Including DPYD on Cancer Genetic Panels to Prevent Fatal Fluoropyrimidine Toxicity

Authors:
Daniel L. Hertz
Search for other papers by Daniel L. Hertz in
Current site
Google Scholar
PubMed
Close
 PharmD, PhD
and
Vaibhav Sahai
Search for other papers by Vaibhav Sahai in
Current site
Google Scholar
PubMed
Close
 MBBS, MS
Restricted access

Disclosures: The authors have disclosed that they have not received any financial considerations from any person or organization to support the preparation, analysis, results, or discussion of this article.

Correspondence: Daniel L. Hertz, PharmD, PhD, Department of Clinical Pharmacy, University of Michigan College of Pharmacy, 1100 North University Building, Room 2560C, Ann Arbor, MI 48109-1065. Email: DLHertz@med.umich.edu
  • Collapse
  • Expand
  • 1.

    Benson AB III, Venook AP, Al-Hawary M, et al.. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 1.2020. Accessed February 21, 2020. To view the most recent version, visit NCCN.org.

    • PubMed
    • Export Citation
  • 2.

    Benson AB III, Venook AP, Al-Hawary M, et al.. NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer. Version 1.2020. Accessed February 21, 2020. To view the most recent version, visit NCCN.org.

    • PubMed
    • Export Citation
  • 3.

    Tempero MA, Malafa MP, Al-Hawary M, et al.. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 1.2020. Accessed February 21, 2020. To view the most recent version, visit NCCN.org.

    • PubMed
    • Export Citation
  • 4.

    Benson AB III, D’Angelica MI, Abbott DE, et al.. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. Version 4.2019. Accessed February 21, 2020. To view the most recent version, visit NCCN.org.

    • PubMed
    • Export Citation
  • 5.

    Ajani JA, D’Amico TA, Bentrem DJ, et al.. NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. Version 4.2019. Accessed February 21, 2020. To view the most recent version, visit NCCN.org.

    • PubMed
    • Export Citation
  • 6.

    Pfister DG, Spencer S, Adelstein D, et al.. NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 1.2020. Accessed February 21, 2020. To view the most recent version, visit NCCN.org.

    • PubMed
    • Export Citation
  • 7.

    Armstrong DK, Alvarez RD, Bakkum-Gomez, et al.. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer. Version 3.2019. Accessed February 21, 2020. To view the most recent version, visit NCCN.org.

    • PubMed
    • Export Citation
  • 8.

    Gradishar WJ, Anderson BO, Abraham J, et al.. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3.2020. Accessed February 21, 2020. To view the most recent version, visit NCCN.org.

    • PubMed
    • Export Citation
  • 9.

    Meulendijks D, Henricks LM, Sonke GS, et al.. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 2015;16:16391650.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Amstutz U, Henricks LM, Offer SM, et al.. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 2018;103:210216.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Rai K, Batukbhai BDO, Brooks GA. Risk of treatment-related death in carriers of pathogenic DPYD polymorphisms treated with fluoropyrimidine chemotherapy: a systematic review and patient-level analysis [abstract]. J Clin Oncol 2019;37(Suppl):Abstract e15132.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Institute of Medicine. Evolution of Translational Omics: Lessons Learned and the Path Forward. Washington, DC: The National Academies Press; 2012.

    • PubMed
    • Export Citation
  • 13.

    Deenen MJ, Meulendijks D, Cats A, et al.. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol 2016;34:227234.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Henricks LM, Lunenburg CATC, de Man FM, et al.. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 2018;19:14591467.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Sepulveda AR, Hamilton SR, Allegra CJ, et al.. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Clin Oncol 2017;35:14531486.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Labianca R, Nordlinger B, Beretta GD, et al.. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi6472.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Toffoli G, Innocenti F, Polesel J, et al.. The genotype for DPYD risk variants in patients with colorectal cancer and the related toxicity management costs in clinical practice. Clin Pharmacol Ther 2019;105:9941002.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Hertz DL, Glatz A, Pasternak AL, et al.. Integration of germline pharmacogenetics into a tumor sequencing program [published online July 23, 2018]. JCO Precis Oncol, doi: 10.1200/PO.18.00011

    • Crossref
    • PubMed
    • Export Citation
  • 19.

    Daly MB, Pilarski R, Berry MP, et al.. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 3.2019. Accessed June 27, 2019. To view the most recent version, visit NCCN.org.

    • PubMed
    • Export Citation
  • 20.

    Neben CL, Zimmer AD, Stedden W, et al.. Multi-gene panel testing of 23,179 individuals for hereditary cancer risk identifies pathogenic variant carriers missed by current genetic testing guidelines. J Mol Diagn 2019;21:646657.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 4097 411 28
PDF Downloads 1394 201 29
EPUB Downloads 0 0 0